Back to Results
First PageMeta Content
CRLX101 / Nanoparticle / Docetaxel / Organic chemistry / Nanotechnology / Nanomaterials / Chemistry


BioCentury, THE BERNSTEIN R EPORT
Add to Reading List

Document Date: 2013-06-24 09:06:43

Open Document

File Size: 49,82 KB

Share Result on Facebook

City

Maastricht / Cambridge / Petah Tikva / Pasadena / /

Company

Mersana Therapeutics Inc. / Cerulean Pharma Inc. / Netherlands Mersana Therapeutics Inc. / Bind Therapeutics Inc. / Calando Pharmaceuticals Inc. / Innovatiefonds Limburg / Teva Pharmaceutical Industries Ltd. / Arrowhead Research Corp. / Nedermaas Ventures / Thuja Capital / BioGeneration Ventures / COMPANIES AND INSTITUTIONS MENTIONED Arrowhead Research Corp. / /

Country

Israel / /

Currency

USD / /

Event

FDA Phase / Business Partnership / /

Facility

Aachen University / Utrecht University / Cancer Institute Corporate / /

IndustryTerm

platform technology / manufacturing process / /

MedicalCondition

cancers / Cancer / castration-resistant prostate cancer / CriPec polymeric nanoparticles Disease / advanced solid tumors / neovasculature surrounding tumors / premature dissociation / non-small cell lung cancer / /

Organization

Joost Holthuis University / Aachen University / Utrecht University / /

Person

Cristianne Rijcken / Kai-Jye Lou / Cristal Therapeutics / covering CriPec platform technology Cristal / /

Position

CEO / Writer / cofounder and CEO / /

Product

CRLX101 / HIF1A / FOLH1 / CriPec / /

ProvinceOrState

California / Massachusetts / /

Technology

alpha / pharmacokinetics / linear CDP technology / CriPec platform technology / /

SocialTag